Magnetic Resonance - Technology Information Portal Welcome to MRI Technology
Info
  Sheets

Out-
      side
 



 
 'Lantheus Medical Imaging, Inc.' 
SEARCH FOR    
 
  2 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Result : Searchterm 'Lantheus Medical Imaging, Inc.' found in 1 term [] and 2 definitions []
1 - 3 (of 3)     
Result Pages : [1]
Searchterm 'Lantheus Medical Imaging, Inc.' was also found in the following services: 
spacer
News  (11)  
 
Lantheus Medical Imaging, Inc.
 
www.radiopharm.com Lantheus Medical Imaging is a worldwide leader in medical imaging, with headquarters in North Billerica, Massachusetts, and nearly 700 employees worldwide with offices in Puerto Rico, Canada, and Australia.
The product portfolio includes ABLAVAR™ (gadofosveset trisodium) a blood pool contrast agent for magnetic resonance angiography MRA, Cardiolite® (Kit for the preparation of Technetium Tc99m Sestamibi), a cardiac perfusion imaging agent and DEFINITY® Vial for (Perflutren Lipid Microsphere) injectable suspension, the leading cardiac ultrasound contrast agent in the US.

MRI Contrast Agents:
Contact Information
MAIL
Lantheus Medical Imaging
Bldg. 200-2, 331 Treble Cove Rd.
N. Billerica, MA 01862
USA
PHONE
+1-800-362-2668
FAX
+1-978-436-7501
spacer
 
• Share the entry 'Lantheus Medical Imaging, Inc.':  Facebook  Twitter  LinkedIn  

• View the NEWS results for 'Lantheus Medical Imaging, Inc.' (5).Open this link in a new window.
Searchterm 'Lantheus Medical Imaging, Inc.' was also found in the following service: 
spacer
Ultrasound  (1) Open this link in a new window
ABLAVAR™InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
ABLAVAR™ (formerly named Vasovist™) is a blood pool agent for magnetic resonance angiography (MRA), which opens new medical imaging possibilities in the evaluation of aortoiliac occlusive disease (AIOD) in patients with suspected peripheral vascular disease.
ABLAVAR™ binds reversibly to blood albumin, providing imaging with high spatial resolution up to 1 hour after injection, due to its high relaxivity and to the long lasting increased signal intensity of blood.
As with other contrast media: the possibility of serious or life-threatening anaphylactic or anaphylactoid reactions, including cardiovascular, respiratory and/or cutaneous manifestations, should always be considered.

WARNING:
NEPHROGENIC SYSTEMIC FIBROSIS
Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.

See also Cardiovascular Imaging, Adverse Reaction, Molecular Imaging, and MRI Safety.
Drug Information and Specification
NAME OF COMPOUND
Diphenylcyclohexyl phosphodiester-Gd-DTPA, gadofosveset trisodium, MS-325
CENTRAL MOIETY
Gd2+
CONTRAST EFFECT
T1, predominantly positive enhancement
20-45 mmol-1sec-1, Bo=0,47T
PHARMACOKINETIC
Intravascular
825 mOsmol/kg H2O
CONCENTRATION
244 mg/mL, 0.25mmol/mL
DOSAGE
0.12 mL/kg, 0.03 mmol/kg
PREPARATION
ready to use
DEVELOPMENT STAGE
FDA approved
DISTRIBUTOR
See below
PRESENTATION
10 mL vials
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT
STAGE
DISTRIBUTOR
EU
Approved
USA, Canada, Australia
ABLAVAR™
Approved
spacer

• View the DATABASE results for 'ABLAVAR™' (3).Open this link in a new window


• View the NEWS results for 'ABLAVAR™' (1).Open this link in a new window.
 
Further Reading:
  Basics:
Ablavar Prescribing Information
   by www.ablavar.com    
  News & More:
The first FDA-approved blood-pool MR agent offers additional time for imaging and possibly some new applications
Thursday, 1 July 2010   by www.radiologytoday.net    
MRI Resources 
Raman Spectroscopy - Education pool - Safety Products - PACS - MRI Reimbursement - Contrast Agents
 
Vasovist™InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Vasovist™ is an albumin-targeted intravascular contrast agent. It is indicated for contrast enhanced MR angiography (CE-MRA) for the visualization of abdominal or limb vessels in patients with suspected or known vascular disease. After IV injection, Vasovist™ binds reversibly to human albumin in plasma, which results in long-lasting increased relaxivity. Imaging from 5 to 50 min is possible. A small unbound portion is, by glomerular filtration, eliminated by the kidneys.
AngioMARK® was the formerly trade name and MS-325 the research name. Currently the phase III clinical trials are completed to determine its efficacy for peripheral vascular disease and coronary artery disease.
In the U.S., EPIX received an approvable letter from the U.S. Food and Drug Administration (FDA) for Vasovist™ in January 2005. In 2009, Epix Pharmaceuticals has sold the U.S., Canadian and Australian rights for its blood pool agent (now named ABLAVAR™), to Lantheus Medical Imaging, Inc..

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or the liver transplantation period.

See also MRI Safety.
Drug Information and Specification
NAME OF COMPOUND
Diphenylcyclohexyl phosphodiester-Gd-DTPA, gadofosveset trisodium, MS-325
CENTRAL MOIETY
Gd2+
CONTRAST EFFECT
T1, predominantly positive enhancement
20-45 mmol-1sec-1, Bo=0,47T
PHARMACOKINETIC
Intravascular, short elimination half life
825 mOsmol/kg H2O
CONCENTRATION
244 mg/mL, 0.25mmol/mL
DOSAGE
0.12 mL/kg, 0.03 mmol/kg
PREPARATION
ready to use
DEVELOPMENT STAGE
approved
DISTRIBUTOR
See below
PRESENTATION
10 mL vials
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT
STAGE
DISTRIBUTOR
EU
Vasovist™
?
?
North America, Australia
for sale
spacer

• View the DATABASE results for 'Vasovist™' (7).Open this link in a new window

 
Further Reading:
  Basics:
EPIX Medical's new multimedia Web site features AngioMARK images in 3D
Friday, 5 March 1999
MRI technology combined with contrast agent optimizes diagnosis of cardiovascular disease
1999
Searchterm 'Lantheus Medical Imaging, Inc.' was also found in the following services: 
spacer
News  (11)  
 
     1 - 3 (of 3)     
Result Pages : [1]
 Random Page
 
Share This Page
FacebookTwitterLinkedIn

MR-TIP    
Community   
User
Pass
Forgot your UserID/Password ?    



MRI is trending to low field magnets :
reduced costs will lead to this change 
AI will close the gap to high field 
only in remote areas 
is only temporary 
never 

Look
      Ups





MR-TIP.com uses cookies! By browsing MR-TIP.com, you agree to our use of cookies.

Magnetic Resonance - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • Medical-Ultrasound-Imaging • 
Copyright © 2003 - 2024 SoftWays. All rights reserved. [ 29 March 2024]
Terms of Use | Privacy Policy | Advertising
 [last update: 2024-02-26 03:41:00]